Management of recurrent cervical cancer

Chang Gung Medical Journal

Volumn 27, Issue 10, 2004, Pages 711-717

  Lai, Chyong Huey ^a,b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Posttherapy surveillance; Recurrent cervical carcinoma; Restaging; Salvage therapy

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; MITOLACTOL; PACLITAXEL; TOPOTECAN;

CANCER ADJUVANT THERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; COMORBIDITY; EARLY DIAGNOSIS; EVISCERATION; FEMALE; HUMAN; INTRAOPERATIVE PERIOD; LYMPH NODE METASTASIS; MORBIDITY; PELVIS SURGERY; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RADICAL HYSTERECTOMY; RECURRENT CANCER; REVIEW; SURVIVAL RATE; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT OUTCOME; UTERINE CERVIX CANCER;

COMBINED MODALITY THERAPY; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; PELVIC EXENTERATION; PROGNOSIS; UTERINE CERVICAL NEOPLASMS;

EID: 11144352119     PISSN: 02558270     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Department of Health, the Executive Yuan. Cancer registry annual report in Taiwan (R.O.C.), 2000;2004.
2. International Federation of Gynecology and Obstetrics, FIGO staging of gynecologic cancers: cervical and vulva. Int J Gynecol Cancer 1995;5:319-24.
3. Waggoner SE. Cervical cancer. Lancet 2003;361:2217-25.
4. Landoni F, Maneo A, Colombo A, Placa F, Milani R, Perego P, et al. Randomized study of radical surgery versus radiotherapy for stage IB-IIA cervical cancer. Lancet 1997;350:535-40.
5. Lai CH, Hong JH, Hsueh S, Ng KK, Chang TC, Tseng CJ, et al. Preoperative prognostic variables and the impact of postoperative adjuvant therapy on the outcomes of stage IB or II cervical carcinoma patients with or without pelvic lymph node metastases. Cancer 1999;85:1537-46.
6. Burke TW, Hoskins WJ, Heller PB, Shen MC, Weiser EB, Park RC. Clinical patterns of tumor recurrence after radical hysterectomy in stage IB cervical carcinoma. Obstet Gynecol 1987;69:382-5.
7. Wang CJ, Lai CH, Huang HJ, Hong JH, Chou HH, Huang KG, et al. Recurrent cervical carcinoma after primary radical surgery. Am J Obstet Gynecol 1999;181:518-24.
8. Soisson AP, Geszler G, Soper JT, Berchuck A, Clerke-Pearson DL. A comparison of symptomatology, physical examination, and vaginal cytology in the detection of recurrent cervical carcinoma after radical hysterectomy. Obstet Gynecol 1990;76:106-9.
9. Eralp Y, Saip P, Sakar B, Kucucuk S, Aydiner A, Dincer M, et al. Prognostic factors and survival in patients with metastatic or recurrent carcinoma of the uterine cervix. Int J Gynecol Cancer 2002;13:497-504.
10. Sommers GM, Grigsby PW, Perez CA, Camel HM, Kao MS, Galakatos AE, et al. Outcome of recurrent cervical carcinoma following definitive irradiation. Gynecol Oncol 1989;35:150-5.
11. Hong JH, Tsai CS, Lai CH, Chang TC, Wang CC, Lee SP, et al. Recurrent squamous cell carcinoma of cervix following definitive radiotherapy. Int J Radiat Oncol Biol Phys 2004;60:249-57.
12. Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999;15:1144-51.
13. Keys HM, Bundy BN, Stehman FB, Muderspach LI, Chafe WE, Suggs III CL, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage Ib cervical carcinoma. N Engl J Med 1999;15:1154-61.
14. Eifel PJ, Winter K, Morris M, Levenback C, Grigsby PW, Copper J, et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of Radiation Therapy Oncology Group (RTOG) study 90-01. J Clin Oncol 2004;22:872-80.
15. Chang TC, Lai CH, Hsueh S, Huang KG, Chou HH, Tseng CJ, et al. Randomized trial of neoadjuvant cisplatin, vincristine, bleomycin and radical hysterectomy versus radiation therapy for bulky stage IB and IIA cervical cancer. J Clin Oncol 2000;18:1740-7.
16. Curtin JP, Hoskins WJ, Venkatraman ES, Almadrones L, Podratz KC, Long H, et al. Adjuvant chemotherapy versus chemotherapy plus pelvic irradiation for high-risk cervical cancer patients after radical hysterectomy and pelvic lymphadenectomy (RH-PLND): a randomized phase III trial. Gynecol Oncol 1996;61:3-10.
17. Lai CH, Tang SG, Chang TC, Tseng CJ, Chou HH, Huang KG, et al. Implications of a failed prospective trial of adjuvant therapy after radical hysterectomy for stage Ib-IIa cervical carcinoma with pelvic node metastases. Chang Gung Med J 1998;21:291-9.
18. Peters WA, Liu PY, Barrett II RJ, Stock RJ, Monk BJ, Berek JF, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjunctive therapy after radical surgery in high-risk, early-stage carcinoma of the cervix. J Clin Oncol 2000;18:1606-13.
19. Chou HH, Wang CC, Lai CH, Hong JH, Ng KK, Chang TC, et al. Isolated paraaortic lymph node recurrence after definitive irradiation for cervical carcinoma. Int J Radiat Oncol Biol Phys 2001;51:442-8.
20. Hatano K, Sekiya Y, Araki H, Sakai M, Togawa T, Narita, Y, et al. Evaluation of the therapeutic effect of radiotherapy on cervical cancer using magnetic resonance imaging. Int J Radiat Oncol Biol Phys 1999;45:639-644.
21. Chan YM, Ng TY, Ngan HY, Wong LC. Monitoring of serum squamous cell carcinoma antigen levels in invasive cervical cancer: is it cost-effective? Gynecol Oncol 2002;84:7-11.
22. Esajas MD, Duk JM, de Bruijn HW, Aalders JG, Willemse PH, Sluiter W, et al. Clinical value of routine serum squamous cell carcinoma antigen in follow-up of patients with early-stage cervical cancer. J Clin Oncol 2001;19:3960-6.
23. Ohno T, Nakayama Y, Nakamoto S, Kato S, Imai R, Nonaka T, Ishikawa H, et al. Measurement of serum squamous cell carcinoma antigen levels as a predictor of radiation response in patients with carcinoma of the uterine cervix. Cancer 2003;97:3114-20.
24. Bolli JA, Doering DL, Bosscher JR, Day TG, Jr., Rao CV, Owens K, et al. Squamous cell carcinoma antigen: clinical utility in squamous cell carcinoma of the uterine cervix. Gynecol Oncol 1994;55:169-73.
25. Tabata T, Takeshim N, Tanaka N, Hirai Y, Hasumi K. Clinical value of tumor markers for early detection of recurrence in patients with cervical adenocarcinoma and adenosquamous carcinoma. Tumor Biol 2000;21:375-80.
26. Sakurai H, Mitsuhashi N, Takahashi M, Akimoto T, Muramatsu H, Ishikawa H, et al. Analysis of recurrence of squamous cell carcinoma of the uterine cervix after definitive radiation therapy alone: patterns of recurrence, latent periods, and prognosis. Int J Radiat Oncol Biol Phys 2001;50:1136-44.
27. Sasaoka M, Fuwa N, Asano A, Matsumoto A, Katou E, Ito Y. Patterns of failure in carcinoma of the uterine cervix treated with definitive radiotherapy alone. Am J Clin Oncol 2001;24:586-590.
28. Thomas GM, Dembo AJ, Myhr T, Black B, Pringle JF, Rawlings G. Long-term results of concurrent radiation and chemotherapy for carcinoma of the cervix recurrent after surgery. Int J Gynecol Cancer 1993;3:193-8.
29. Anderson TM, McMahon JJ, Nwogu CE, Pombo MW, Urschel JD, Driscoll DL, et al. Pulmonary resection in metastatic uterine and cervical malignancies. Gynecol Oncol 2001;83:472-6.
30. Kaseki H, Yasui K, Niwa K, Mizuno K, Inoue T, Ota M. Hepatic resection for metastatic squamous cell carcinoma from the uterine cervix. Gynecol Oncol 1992;44:284-7.
31. Shingleton HM, Soong SJ, Gelder MS, Hatch KD, Baker VV, Austin JM. Clinical and histological fators predicting recurrence and survival after pelvic exenteration for cancer of the cervix. Obstet Gynecol 1989;73:1027-34.
32. Hacker NF. Cervical cancer. In: Berek JS and Hacker NF, eds. Practical Gynecologic Oncology, 3rd ed. Pliladelphia: Lippincott Williams & Wilkins, 2000:345-405.
33. Ramirez PT, Modesitt SC, Morris M, Edwards CL, Bevers MW, Wharton JT, et al. Funtional outcomes and complications of continent urinary diversions in patients with gynecologic malignancies. Gynecol Oncol 2002;85:285-91.
34. Miller B, Morris M, Rutledge F, Mitchell MF, Atdinson EN, Burke TW, et al. Aborted exenteratice prodcedures in recurrent cervical cancer. Gynecol Oncol 1993;50:94-9.
35. Prempree T, Amornmarn R, Villasanta U, Kwon T, Scott RM. Retreatment of very late recurrent invasive squamous cell carcinoma of the cervix with irradiation. II. Criteria for patients selection to achieve the success. Cancer 1984;54:1950-5.
36. Rubin SC, Hoskins WJ, Lewis JL. Radical hysterectomy for recurrent cervical cancer following radiation therapy. Gynecol Oncol 1987;27:316-24.
37. Coleman RL, Keeney ED, Freedman RS, Burke TW, Eifel PJ, Rutledge FN. Radical hysterectomy for recurrent carcinoma of the uterine cervix after radiotherapy. Gynecol Oncol 1994;55:29-35.
38. Rutledge S, Carey MS, Prichard H, Allen HH, Kocha W, Kirk ME. Conservative surgery for recurrent or persistent carcinoma of the cervix following irradiation: is exenteration always necessary? Gynecol Oncol 1994;52:353-9.
39. Hockel M, Schlenger K, Hamm H, Knapstein PG, Hohenfellner R, Rosier HP. Five-year experience with combined operative and radiotherapeutic treatment of recurrent gynecologic tumors infiltrating the pelvic wall. Cancer 1996;77:1918-33.
40. Mahe MA, Gerard JP, Duois JB, Roussel A, Bussieres E, Delannes M, et al. Intraoperative radiation therapy in recurrent carcinoma of the uterine cervix: report of the French Intraoperative Group on 70 patients. Int J Radiat Oncol Biol Phys 1996;34:21-6.
41. Carton GR, Gunderson LL, Webb MJ, Wilson TO, Martenson JA, Cha SS, et al. Intraoperative radiation therapy in gynecologic cancer: update of the experience at a single institution. Int J Radiat Oncol Biol Phys 1997;37:839-43.
42. Martinez-Monge R, Jurdo M, Aristu JJ, Moreno M, Camberiro M, Perez-Ochoa A, et al. Intraopertive electron beam radiotherapy during radical surgery for locally advanced and recurrent cervical cancer. Gynecol Oncol 2001;82:538-43.
43. Hockel M. Laterally extended endopelvic resection: Novel surgical treatment of locally recurrent cervical carcinoma involving the pelvic sidewall. Gynecol Oncol 2003;91:369-77.
44. Thigpen T, Vance RB, Khansur T. Carcinoma of the uterine cervix: Current status and future directions. Semin Oncol 1994;21:S43-54.
45. Mutch DG, Bloss JD. Gemcitabine in cervical cancer. Gynecol Oncol 2003;90:S8-15.
46. Fiorica JV. The role of topotecan in the treatment of advanced cervical cancer. Gynecol Oncol 2003;90:S16-21.
47. Moore DH, Blessing JA, McQuellon RP, Thaler HT, Cella D, Benda J, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 2004;22:3113-9.
48. Gambhir SS, Czenin J, Schwimmer J, Silverman DHS, Coleman RE, Phelps MW. A tabulated summary of the FDG PET literature. J Nucl Med 2001;42:S1-93.
49. Rose PG, Adler LP, Rodriguez M, Faulhaber PF, Abdul-Karim FW, Miraldi F. Positron emission tomography for evaluating para-aortic nodal metastasis in locally advanced cervical cancer before surgical staging: a surgicopathologic study. J Clin Oncol 1999;17:41-5.
50. Tasi CS, Chang TC, Lai CH, Tsai CC, Ng KK, Hseuh S, et al. A preliminary report of using FDG-PET to detect extrapelvic lesions in cervical cancer patients with enlarged pelvic lymph nodes shown on MRI/CT images. Int J Radiat Oncol Biol Phys 2004;58:1506-12.
51. Yen TC, Ng KK, Ma SY, Chou HH, Tsai CS, Hsueh S, et al. Value of dual-phase 2-fluoro-2-deoxy-d-glucose positron emission tomography in cervical cancer. J Clin Oncol 2003;21:3651-8.
52. l8F]-2-fluoro-2-deoxy-glucose positron emission tomography for detection of para-aortic lymph node metastases in cervical cancer patients. J Nucl Med 2003;44:1775-83.
53. Nakamoto Y, Eisbruch A, Achtyes ED, Sugawara Y, Reynolds KR, Johnston CM, et al. Prognostic value of positron emission tomography using F-18-fluorodeoxyglucose in patients with cervical cancer undergoing radiotherapy. Gynecol Oncol 2002;84:289-95.
54. Havrilesky LJ, Wong TZ, Secord AA, Berchuck A, Clarke-Pearson DL, Jones EL. The role of PET scanning in the detecting of recurrent cervical cancer. Gynecol Oncol 2003;90:186-90.
55. l8F-fluoro-2-deoxyglusose positron emission tomography in the evaluation of recurrent cervical cancer. Anticancer Res 2001;21:2957-62.
56. Grigsby PW, Siegel BA, Dehdashti F, Mutch DG. Posttherapy surveillance monitoring of cervical cancer by FDG-PET. Int J Radiat Oncol Biol Phys 2003;55:907-13.
57. Ryu SY, Kim MH, Choi SC, Choi CW, Lee KH. Detection of early recurrence with 18F-FDG in patients with cervical cancer. J Nucl Med 2003;44:347-52.
58. Chang TC, Law KS, Hong JH, Lai CH, Yen TC, Ng KK, et al. Positron emission tomography for unexplained serum SCC-Ag elevation in cervical cancer patients -a phase II Study. Cancer 2004;101:164-71.
59. Lai CH, Huang KG, See LC, Yen TC, Ma SY, Tsai CS, et al. Restaging of recurrent cervical cancer with dual-phase positron emission tomography. Cancer 2004;100:544-52.
60. l8F-fluoro-D-deoxyglucose positron emission tomography for recurrent cervical cancer. J Nucl Med (in press).